Skip to main content

Female Sexual Arousal Disorder

2
Pipeline Programs
4
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 3 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Daré Bioscience
Daré BioscienceCA - San Diego
1 program
1
SildenafilPhase 21 trial
Active Trials
NCT04948151Unknown440Est. Dec 2021
Pfizer
PfizerNEW YORK, NY
1 program
1
Sildenafil 100 mgPhase 21 trial
Active Trials
NCT00640458Completed20Est. Mar 2007
Kern Pharma
Kern PharmaSpain - Barcelona
1 program
Tribulus TerrestrisN/A1 trial
Active Trials
NCT03820453Unknown110Est. Aug 2019
Palatin Technologies
1 program
bremelanotidePHASE_2Peptide1 trial
Active Trials
NCT01382719Completed612Est. Sep 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Daré BioscienceSildenafil
Palatin Technologiesbremelanotide
PfizerSildenafil 100 mg
Kern PharmaTribulus Terrestris

Clinical Trials (4)

Total enrollment: 1,182 patients across 4 trials

NCT04948151Daré BioscienceSildenafil

Multi-Center Study to Evaluate the Efficacy and Safety of Sildenafil Cream (3.6%) in Premenopausal Patients With Female Sexual Arousal Disorder

Start: Jun 2021Est. completion: Dec 2021440 patients
Phase 2Unknown
NCT01382719Palatin Technologiesbremelanotide

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

Start: Jun 2011Est. completion: Sep 2012612 patients
Phase 2Completed
NCT00640458PfizerSildenafil 100 mg

Study to Investigate Effect of Sildenafil on Clitoral Engorgement as Measured by Magnetic Resonance Imaging (MRI) in Pre-menopausal Women With Female Sexual Arousal Disorder

Start: Apr 2004Est. completion: Mar 200720 patients
Phase 2Completed
NCT03820453Kern PharmaTribulus Terrestris

Clinical Trial to Investigate the Effectiveness of a Dietary Supplement in Increasing Libido and Sexual Function in Postmenopausal Women.

Start: Oct 2018Est. completion: Aug 2019110 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.